STOCK TITAN

Alkermes settles LYBALVI patent dispute with Teva

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Alkermes plc said its wholly owned indirect subsidiaries, Alkermes, Inc. and Alkermes Pharma Ireland Limited, entered into a confidential settlement and license agreement with Teva Pharmaceuticals, Inc. concerning a lawsuit about certain U.S. patents for all dosage strengths of LYBALVI. The agreement grants Teva a limited, non-exclusive, royalty-free, non-transferable and non-sublicensable license to make, have made, use, import, sell and offer for sale products made under its ANDA in the United States beginning November 12, 2039, or, if Alkermes obtains pediatric exclusivity, May 12, 2040, or earlier under certain circumstances.

The parties filed a joint Stipulation of Dismissal with Prejudice on November 9, 2026, to dismiss the pending proceedings. The settlement agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
License start date November 12, 2039 United States license start date under the agreement
Alternate license start date May 12, 2040 If Alkermes obtains pediatric exclusivity
Dismissal stipulation date November 9, 2026 The parties filed a joint stipulation to dismiss the pending proceedings
abbreviated new drug application regulatory
"Teva’s abbreviated new drug application (“ANDA”) No. 220379"
An abbreviated new drug application is a regulatory submission used to gain approval to market a generic version of an already approved prescription medicine by showing it is equivalent in effect and safety to the original product, without repeating full clinical trials. For investors, an approval signals a lower-cost competitor entering the market that can quickly capture sales from the branded drug, similar to a generic knock‑off replacing a name‑brand item on store shelves.
pediatric exclusivity regulatory
"if Alkermes obtains pediatric exclusivity"
Pediatric exclusivity is a regulatory reward that gives a drug maker extra protected selling time—typically a six‑month extension—if the company conducts studies showing the medicine is safe and effective for children. For investors, it matters because that extra time is like a temporary shield that delays generic competition and can materially extend revenue from a product, affecting a drug’s cash flow, valuation and investment returns.
non-exclusive, royalty-free, non-transferable, non-sublicensable limited license technical
"non-exclusive, royalty-free, non-transferable, non-sublicensable limited license"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When can Teva sell LYBALVI under the ALKS settlement?

The license permits Teva to sell and offer for sale products made under its ANDA in the United States beginning November 12, 2039, or, if Alkermes obtains pediatric exclusivity, May 12, 2040, or earlier under certain circumstances.

What happened to the LYBALVI patent case involving ALKS?

The parties filed a joint Stipulation of Dismissal with Prejudice on November 9, 2026, to dismiss the pending proceedings. The settlement agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
False0001520262Alkermes plc.00015202622026-11-062026-11-06

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 6, 2026

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

 

Ireland

 

001-35299

 

98-1007018

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

 

 

 

 

 

Connaught House, 1 Burlington Road

Dublin 4, Ireland D04 C5Y6

(Address of principal executive offices)

 

Registrant's telephone number, including area code: + 353-1-772-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

☐

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

☐

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

☐

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Ordinary shares, $0.01 par value

 

ALKS

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

 

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


 

Item 1.01 Entry into a Material Definitive Agreement.

 

On November 6, 2026, Alkermes, Inc. and Alkermes Pharma Ireland Limited (together, “Alkermes”), two wholly-owned indirect subsidiaries of Alkermes plc (the “Company”), entered into a Confidential Settlement and License Agreement (the “Settlement Agreement”) with Teva Pharmaceuticals, Inc. (“Teva”, and together with Alkermes, the “parties”), resolving a patent infringement lawsuit relating to all dosage strengths of the Company’s product LYBALVI® (olanzapine and samidorphan). The lawsuit was brought by Alkermes against Teva in the U.S. District Court for the District of New Jersey for infringement by Teva’s abbreviated new drug application (“ANDA”) No. 220379 of certain of the Company’s Orange Book-listed United States Patents for LYBALVI. Pursuant to the Settlement Agreement, Alkermes will grant Teva a non-exclusive, royalty-free, non-transferable, non-sublicensable limited license to make, have made, use, import, sell and offer for sale Teva’s products made under ANDA No. 220379 in the United States beginning on November 12, 2039, or, if Alkermes obtains pediatric exclusivity, on May 12, 2040, or earlier under certain circumstances.

 

On November 9, 2026, the parties filed a joint Stipulation of Dismissal with Prejudice to dismiss the pending legal proceedings. The Settlement Agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. The foregoing description of certain provisions of the Settlement Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Settlement Agreement, which the Company intends to file as an exhibit to its Annual Report on Form 10-K for the year ending December 31, 2026.

 

 

2


 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ALKERMES PLC

 

 

Date: November 12, 2026

By:

 

/s/ David J. Gaffin

 

 

 

David J. Gaffin

 

 

 

Secretary

 

3


Filing Exhibits & Attachments

1 document

Keep reading